

## Drug Monograph

Drug/Drug Class: **Lupaneta™ Pack (leuprolide acetate and norethindrone acetate) kit / gonadotropin-releasing hormone and progestin**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
<b>Dosage Forms:</b>	Each kit of Lupaneta™ Pack contains one syringe containing 11.25 mg leuprolide acetate and one 90 count bottle of norethindrone acetate 5 mg tablets.
<b>Manufacturer:</b>	Manufactured for: AbbVie Inc. North Chicago, IL 60064 Leuprolide Acetate By: Takeda Pharmaceutical Company Limited Osaka, Japan 540-8645 Norethindrone By: Glenmark Generics Ltd. Colvale-Bardez, Goa 403 513, India
<b>Indications:</b>	Lupaneta™ Pack is indicated for the initial management of the painful symptoms of endometriosis and ongoing management of recurrent symptoms.
<b>Costs:</b>	\$857.06 per kit of Lupaneta™ Pack WholesaleAcquisitionCost
<b>Summary of Findings:</b>	The Division recommends Open Access status for this product.
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required <input checked="" type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input type="checkbox"/> Clinical Edit
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Non-Preferred Agent <input type="checkbox"/> Appropriate Indications <input checked="" type="checkbox"/> No PA Required

Prepared By: Katie Wilbers, PharmD  
Date: May 13, 2014